| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52687-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52679-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34897-10ug | |||
| Carrier-Free | NBP2-34897-1mg | |||
| Carrier-Free | NBP2-34897-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12021-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34909-10ug | |||
| Carrier-Free | NBP2-34909-1mg | |||
| Carrier-Free | NBP2-34909-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35029-10ug | |||
| Carrier-Free | NBP2-35029-1mg | |||
| Carrier-Free | NBP2-35029-500ug | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Biotin | NBP3-18522-100ug | |||
| Biotin | NBP3-18522-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-11965-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP3-12007-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34998-1mg | |||
| Carrier-Free | NBP2-34998-100ug | |||
| Carrier-Free | NBP2-34998-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35032-10ug | |||
| Carrier-Free | NBP2-35032-1mg | |||
| Carrier-Free | NBP2-35032-500ug | |||
![Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/OX40-Ligand-TNFSF4-Antibody-R4930-Oxelumab-Chimeric-Flow-Cytometry-NBP2-52687-img0001.jpg "Flow Cytometry: OX40 Ligand/TNFSF4 Antibody (R4930 (Oxelumab)) - Chimeric [NBP2-52687] - Human peripheral blood leukocytes were fixed using 2% PFA, permeabilised using 0.5% Triton and stained with unimmunized rabbit IgG antibody (isotype control, black line) or the rabbit IgG-chimeric version of R4930 (NBP2-52687, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-rabbit IgG AlexaFluor 488 antibody at a dilution of 1:1000 and cells analyzed using a FACSCanto flow-cytometer.")
![SDS-Page: Human IL-5 Protein [NBP2-34897]](http://images.novusbio.com/fullsize/Human-IL-5-Protein-SDS-Page-NBP2-34897-img0002.jpg "SDS-Page: Human IL-5 Protein [NBP2-34897]")
![Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.](http://images.novusbio.com/fullsize/IL-9-Antibody-D9302C12-Chimeric-Flow-Cytometry-NBP3-12021-img0001.jpg "Flow Cytometry: IL-9 Antibody (D9302C12) - Chimeric [NBP3-12021] - Mouse splenocytes were stimulated with PMA and Ionomycin in presence of Monensin for 4 hours. The cells were fixed using 2% PFA, permeabilized using 0.5% Triton and stained with anti-Fluorescein IgG antibody (4-4-20; isotype control, black line) or the rabbit IgG version of D9302C12 (NBP3-12021, blue line) at a dilution of 1:100 for 1h at RT. After washing, bound antibody was detected using a goat anti-mouse IgG AlexaFluor(R) 488 antibody at a dilution of 1:1000 and cells were analyzed using a FACSCanto flow-cytometer.")
![SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]](http://images.novusbio.com/fullsize/Recombinant-Rat-IL-10-Protein-SDS-Page-NBP2-61341-img0002.jpg "SDS-Page: Recombinant Rat IL-10 Protein [NBP2-61341]")
![SDS-Page: Human IL-9 Protein [NBP2-34909]](http://images.novusbio.com/fullsize/Human-IL-9-Protein-SDS-Page-NBP2-34909-img0001.jpg "SDS-Page: Human IL-9 Protein [NBP2-34909]")
![SDS-Page: Human IL-16 121 a.a Protein [NBP2-35029]](http://images.novusbio.com/fullsize/Human-IL-16-121-a.a-Protein-SDS-Page-NBP2-35029-img0001.jpg "SDS-Page: Human IL-16 121 a.a Protein [NBP2-35029]")
![SDS-Page: Recombinant Human MIF His Avi-tag Protein [Biotin] [NBP3-18522] - Western blot under reducing and non-reducing conditions](http://images.novusbio.com/fullsize/Recombinant Human MIF His Avi-tag Protein [Biotin]-SDS-Page-NBP3-18522-img0001.jpg "SDS-Page: Recombinant Human MIF His Avi-tag Protein [Biotin] [NBP3-18522] - Western blot under reducing and non-reducing conditions")
![SDS-Page: Human IL-16 130 a.a Protein [NBP2-35032]](http://images.novusbio.com/fullsize/Human-IL-16-130-a.a-Protein-SDS-Page-NBP2-35032-img0001.jpg "SDS-Page: Human IL-16 130 a.a Protein [NBP2-35032]")